Read the latest news featuring experts from the Metabolism Unit.
November 7, 2022
Diet Quality Is Suboptimal or Poor in Large Proportion of Global Population with HIV
Kathleen V. Fitch, MSN, a principal associate in medicine at Massachusetts General Hospital, Steven K. Grinspoon, MD, chief of the Metabolism Unit, and colleagues recently conducted the first analysis of diet quality across a multinational cohort of PWH. In the journal AIDS, they report that diet quality was poor or suboptimal in 42% of individuals.
October 28, 2022
Met U Researchers Work to Discover New Mechanisms and Treatment Strategies for Metabolic Diseases
Established in 2019, researchers in the Metabolism Unit at MGH have worked to discover new pathways of ectopic adipose accumulation, metabolic consequences of abnormal fat distribution and novel treatment strategies for related conditions including NAFLD and cardiovascular disease. Read about our new discoveries and research in this focus piece by the MGH Research Institute!
July 28, 2021
Discovery’s role in addressing the medical skill shortage
When Dr Sumy Thomas returns from a secondment to Harvard Medical School, her research which focuses on work on the endocrine system of patients affected by HIV and AIDS, will be invaluable to the 7.7 million South Africans on antiretroviral treatment.
July 6, 2021
About half of people living with HIV have coronary artery plaque despite low cardiac risk
Significant amounts of atherosclerotic plaque have been found in the coronary arteries of people with HIV, even in those considered by traditional measures to be at low-to-moderate risk of future heart disease, according to a study published in JAMA Network Open. This finding emerged from the global REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) study, in which Massachusetts General Hospital (MGH) is playing a key coordinating role.
Steven Grinspoon, MD, on the Importance of Studying Treatments for Steatosis in HIV
In this video, Steven Grinspoon, MD, talks about why treatments for steatosis in HIV are important to study, including some reasons why most studies in nonalcoholic fatty liver disease (NAFLD) do not include patients with HIV.
September 10, 2020
Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General Population
Theratechnologies Inc.. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in the general population.